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Testicular germ cell tumours (TGCT) represent the most common malignancies in young males. Whereas in 1970s, the survival rate
in patients with metastatic testicular tumours was only 5%, these days, 80% of the patients treated by modern chemotherapy will
survive their disease. The drug that revolutionised the cure rate for patients with metastatic testicular tumours was
cisdiamminedichloroplatinum (cisplatin, CDDP). In vitro experiments on neoplastic germ cell lines showed that their exquisite
sensitivity to CDDP could be attributed to p53-dependent and -independent pathways. Applying cDNA macroarray,
semiquantitative RT–PCR and Western blot analyses, blocking experiments, caspase activity assays, and morphological methods,
we sought here to define the p53-independent pathway(s) involved in the CDDP-induced apoptosis. For this purpose, we used the
human TGCT cell line NCCIT, the mutated p53 of which is known to remain inactive during the course of CDDP-induced apoptosis.
Our experiments showed that within hours of CDDP application, two prototype members of the ‘mitogen-activated protein kinase’
(MAPK) family, designated ‘MAPK ERK kinase’ (MEK) and ‘extracellular signal-regulated kinase’ (ERK), were dually phosphorylated and
caspase-3 became active. Functional assays using MEK inhibitors demonstrated that the phosphorylation of MEK and ERK was
required for the activation of caspase-3 as the executing caspase. Interestingly, experiments with the human malignant germ cell line
NTERA, which is known to possess wild-type p53, revealed the same results. Thus, our data suggest that CDDP mediates its p53-
independent apoptosis-inducing effect on the malignant human testicular germ cells – at least partially – through activation of the
MEK–ERK signalling pathway.
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Except in young males, testicular germ cell tumours (TGCT) are
relatively uncommon malignancies. Despite the paucity, however,
TGCT have become a model for a curable neoplasm even in
advanced stages. The breakthrough in the treatment of metastatic
TGCT was achieved by the drug cisdiamminedichloroplatinum
(cisplatin, CDDP) (Higby et al, 1974; Einhorn, 2002). Cisplatin is a
potent inducer of apoptosis in different cell types and is one of the
most effective and widely used chemotherapeutic agents in the
treatment of human cancers. Although CDDP-induced apoptosis is
known to be the result of its ability to damage DNA (Wyllie et al,
1980; Fichtinger-Schepman et al, 1985; Sorenson and Eastman,
1988; Eastman, 1990), the mechanisms by which CDDP initiates
apoptosis in TGCT are not completely understood.
In mice, elevated levels of wild-type p53 in TGCT seem to
contribute to their sensitivity to DNA-damaging drugs. Using the
murine TGCT cell line F9, Lutzker and Levine (1996) demonstrated
that a functionally inactive p53 protein in neoplastic germ cells
became active following chemotherapy, thus leading to apoptosis.
Although Chresta et al (1996) postulated that a hypersensitivity of
human TGCT to drug-dependent apoptosis may also be associated
with functional p53 , Burger et al (1999) showed that abrogation of
the p53 function does not affect the hypersensitivity of human
TGCT cell lines to chemotherapy. Thus in human TGCT, apoptotic
signalling pathways including those activated by CDDP seem to
be – at least partly – p53 independent (Burger et al, 1997;
Kersemaekers et al, 2002).
In the present study, we sought to define the p53-independent
pathway(s) involved in the CDDP-induced apoptosis of the human
TGCT cell line NCCIT, the p53 of which has been shown to remain
inactive during the process of CDDP-induced apoptosis (Burger
et al, 1999). Based on results from a cDNA macroarray analysis, we
assumed that CDDP exploits the ‘mitogen-activated protein kinase’
(MAPK) signalling pathway to induce apoptosis in NCCIT cells.
Mitogen-activated protein kinase constitutes a superfamily of
kinases that coordinates and transduces incoming signals from
stress and growth factors, hormones and cytokines (Raabe and
Rapp, 2002). The most extensively studied MAPK pathway is the
MAPK kinase (MEK)–extracellular signal-regulated kinase (ERK)
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scascade, where p-MEK1/2 phosphorylates and thereby activates
ERK. Originally the ERK module was thought to mediate cell
proliferation and differentiation. Recent data, however, clearly
show that the ERK activation culminates in phosphorylation of
many proteins with substantial regulatory functions throughout
the cell, coordinating and eliciting conflicting cellular responses
ranging from proliferation and differentiation to apoptosis
(Peyssonnaux and Eychene, 2001; Djeu et al, 2002; Lee and
McCubrey, 2002). Here, we show that in NCCIT cells, CDDP
activates the MEK–ERK signalling pathway, which is followed by a
caspase 3-mediated apoptosis.
MATERIALS AND METHODS
Reagents
Cisplatin was purchased from Hexal (Holzkirchen, Germany),
vinblastin (vin) from Gry-Pharma (Kirchzarten, Germany) and
hydrogen peroxide and two MEK1/2 inhibitors (U0126 and
PD98059) from Sigma (Deisenhofen, Germany). The polyclonal
antibody recognising the activated form of caspase-3 and the
inhibitor of caspase-9 (Z-LEHD-FMK) were obtained from R&D
systems (Wiesbaden, Germany). The horseradish-peroxidase
(HRP)-conjugated polyclonal F(ab)2 fragment against digoxigenin
was obtained from Dako (Hamburg, Germany), the monoclonal
anti-actin antibody from Oncogene (Schwalbach, Germany), and
inhibitors of caspase-3 (Ac-DEVD-CHO) and caspase-8 (Ac-IETD-
CHO) from Pharmingen (Hamburg, Germany). The polyclonal
anti-MEK1/2, anti-phospho-MEK1/2, anti-ERK1/2 and anti-phos-
pho-ERK1/2 antibodies were purchased from Cell Signal Technol-
ogy (Beverly, USA).
Culturing and treatment of TGCT cell lines
The human TGCT cell lines used in this study were NCCIT and
NTERA (American Type Culture Collection, ATCC, Manassas,
USA). NCCIT and NTERA cell lines were grown as monolayers and
maintained in HEPES-buffered RPMI 1640 (Biochrom, Berlin,
Germany) supplemented with 10% foetal calf serum (FCS) (CC
Pro, Neustadt, Germany), 100IUml
 1 penicillin (Sigma, Deisen-
hofen, Germany), 100mgml
 1 streptomycin (Sigma) and 2mML -
glutamine (Life Technologies, Karlsruhe, Germany). Cultures were
incubated at 371C in a humid atmosphere with 5% carbon dioxide
in air. Then, they were plated subconfluent in 75mm
2 flakes and
cultured in serum-free medium 1 day prior to treatment.
For the induction of apoptosis, the cells were then incubated for
2h with different concentrations of CDDP (12.5, 25 and 50mM),
vinblastin (15, 20 and 30mM) or hydrogen peroxide (300, 600 and
1200mM). After washing, cells were incubated in culture medium
for further 6, 9, 12 or 24h.
For the induction of necrosis, the cells were heated for 15, 30 or
60min at 451C (heat stress) or pipetted 10–15 times (mechanical
stress) and were proved to be dead by reculturing.
RNA isolation and cDNA macroarray
For cDNA macroarray, RNA was extracted 6h after CDDP
treatment. Total RNA was extracted from untreated and CDDP-
treated NCCIT cells using ‘Atlast Pure Total RNA Labelling Kit’
(Clontech, Heidelberg, Germany). RNA integrity and quantity was
assessed on an ‘Agilent Bioanalyzer 2100’ with a ‘RNA 6000 Nano
LabChip Kit’ (Agilent Technologies, Waldbronn, Germany). After
DNAse I digestion and addition of biotinylated oligo(dT),
poly(A)
þ RNA was enriched on streptavidin-labelled magnetic
beads from 100mg total RNA. RNA (10mg) templates bound to
the beads were subjected to cDNA synthesis with human CDS
primer mixture and [a-
32P]dATP. Purified cDNA probes
(46.5 10
6c.p.m.) were hybridised to the arrayed human cDNA
membranes (Atlas Human Apoptosis Array, Clontech) under
recommended conditions. Washed membranes were exposed
against the imaging plate for 12h at room temperature and
hybridisation signals were semiquantified on the Personal
Molecular Imager FX System (BioRad, Mu ¨nchen, Germany)
using an image analysis software (BioRad). Gene transcripts
that displayed two-fold or greater changes were considered
significant.
Reverse transcription–PCR
Total cellular RNA from pelleted cells was extracted using RNeasy
Mini Kit (Qiagen, Hilden, Germany). RNA integrity and quantity
was assessed on an Agilent Bioanalyser 2100 with a RNA 6000
Nano LabChip
s-Kit (Agilent Technologies, Waldbronn, Ger-
many). Reverse transcription of 500ng total cellular RNA with
random hexamer primers was performed with Omniscript RT Kit
(Qiagen). Expression of MEK1 and MEK2 was quantitated on an
iCycler iQ real-time detection system (BIORAD, Munich, Ger-
many) with HotStar Taq DNA Polymerase Kit (Qiagen). The 20ml
reaction from the kit was supplemented with 2ml cDNA, 0.6mM
gene-specific primers and SYBR green (MoBiTec, Go ¨ttingen,
Germany). Primers (MWG, Ebersberg, Germany) were designed
using primer3 on-line primer design program (www-genome.wi.-
mit.edu/cgi-bin/primer/primer3_www.cgi).
MEK1 forward primer: 50-TGAGAAGATCAGTGAGCTGG-30;
MEK1 reverse primer: 50-ACTTGATCCAGAGAACCTCC-30; MEK2
forward primer: 50-AACTCAAAGACGATGACTTCG-30; MEK2
reverse primer: 50-CCATGCAAATGCTGATCTCC-30. Acquisition
of fluorescence signals was monitored on the iCycler and ter-
minated, when all reactions reached an amplification plateau
while a template-free control remained at basement level. Data
analysis was carried out with iCycler iQ real-time detection system
software (BioRad). To verify that only specific PCR products
evoked fluorescence signals, PCR products were analysed by
melt curve (BioRad iCycler) and run on 2% agarose gels for
densitometry with E.A.S.Y. Win 32 software (HEROLAB, Wiesloch,
Germany).
Morphological detection, identification and quantification
of apoptosis
May–Giemsa–Grunwald staining Centrifuged cells (2 10
3)
were dried for 24h, fixed in 100% acetone for 10min, stained
with May–Giemsa–Grunwald and embedded in ‘SuperMount
Medium’ (Dako). Apoptotic cells were identified by cellular
shrinkage, nuclear condensation and fragmentation.
In situ end labelling (ISEL) Fixed centrifuged cells (2 10
3) were
rinsed with TBS (50mM Tris-HCl; 150mM NaCl; pH 7,5) containing
10% FCS and 0.3% H2O2 to block endogenous peroxidase activity.
The cells were then incubated for 60min at 371C with 50ml of the
labelling mix (250U ml
 1 terminal transferase, 20mLml
 1
digoxigen–DNA labelling mix at 10  concentration, and
1mmoll
 1 CoCl2 in reaction buffer for terminal transferase
(Roche, Mannheim, Germany)). After being rinsing in TBS, the
cells were blocked with 10% FCS and incubated for 60min with a
rabbit HRP-conjugated F(ab)2 fragment against digoxigenin
(working dilution of 1:500; Dako). 3,30-Diaminobenzidine
(DAB) was next applied as chromogen. Cells with fragmented
DNA revealed nuclear brown signals. DNA-fragmented cells
with intact plasma membrane were considered to be apoptotic.
Negative controls were stained as above but without terminal
transferase.
Immunocytochemistry Fixed centrifuged cells (2 10
3) were
rinsed in TBS containing 10% FCS and 0.3% H2O2 for 10min.
Subsequently, cells were incubated with the polyclonal antibody
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sagainst active caspase-3 for 30min. After washing in TBS, cells
were further incubated with a biotin-conjugated polyclonal goat
anti-rabbit antibody (Dako) for another 20min. The cells were
then incubated with HRP-conjugated streptavidin (Dako) for
20min. The signals were visualised with DAB. Positive cells
showed a brown cytoplasmic staining around the clearly
demarcated nuclei. Controls were stained as above omitting
primary and secondary antibody.
Identification and quantification of apoptosis Apoptotic cells
were identified by nuclear condensation and fragmentation in
MGG staining, by positive cytoplasmic signals for the active form
of caspase-3 in immunocytochemistry or by DNA fragmentation in
ISEL. Percentage of apoptotic cells was calculated as the ratio of
apoptotic cells to 500 cells counted. All experiments were repeated
three times with similar results.
Fluorogenic substrate assay for caspase activity
Caspase-3, caspase-8 and caspase-9 activities were examined using
commercially available fluoremetric kits (caspase-3 and -8 assays,
Santa Cruz Biotechnology, Heidelberg, Germany; caspase-9 assay,
BioRad). Following harvesting and centrifugation, cells (1 10
5)
were lysed in 100ml lysis buffer and incubated for 10min in 100ml
of the reaction buffer supplemented with 100mM of the fluorogenic
peptide substrate Ac-DEVD-AMC, Ac-IETD-AMC, or Ac-LEHD-
AMC to measure caspase-3, -8, or -9 activity, respectively. When
necessary caspase activity was inhibited by Ac-DEVD-CHO
(specific inhibitor of caspase 3), or by Ac-IETD-CHO (specific
inhibitor of caspase-8) or by Z-LEHD-FMK (specific inhibitor of
caspase-9) as recommended by the manufacturer. After 1h, the
release of fluorescent 7-amino-4-trifluoromethyl coumarin was
measured at 5-min intervals on a ‘Fluoroskan Ascent’ (Labsystems,
Helsinki, Finland). All experiments were performed in triplicate
and repeated three times. The data were expressed as the increase
of fluorescence as a function of time.
Western blot
Tumour cells were harvested at 10
7 cells in 500ml of lysis puffer
(0.4% sodium deoxycholate, 1% NP-40, 50mM EGTA, pH 7.4,
10mM Tris pH 7.4, 1mM phenylsulphonyl fluoride (PMSF),
10mgml
 1 leupeptin, 10mgml
 1 aprotinin). After standing on ice
for 20min, the cell lysates were cleared by centrifugation at 5000g
for 10min. The cytosolic supernatants containing equal amounts
of protein were then resolved by electrophoresis on SDS–PAGE gel
(10% (wv
 1) gel). Thereafter, the proteins were transferred
electrophoretically to a nitrocellulose membrane (Schuett, Goettin-
gen, Germany). After blocking in 10mM Tris-HCl buffer, pH 7.4,
containing 150mM NaCl, 0.1% Tween 20 and 5% (wv
 1) nonfat
dry milk, the membrane was treated with appropriate primary
antibodies followed by incubation with HRP-conjugated secondary
antibodies. The antigen–antibody complexes were detected using
a chemiluminescence reagent kit (Amersham Pharmacia Biotech,
Freiburg, Germany).
Cell cycle analysis
To exclude that MEK inhibitors impair the cell cycle, NCCIT cells
were stained by CycleTESTt Plus DNA Reagent Kit (Becton
Dickinson, Heidelberg, Germany) and analysed by flow cytometry
(FACSCalibur, Becton Dickinson), as described by others (Bach
et al, 1991).
RESULTS
Dose- and time-dependent effects of CDDP
Dose-dependent effects of CDDP were determined 24h after
application of 12.5, 25 or 50mM CDDP to the NCCIT cells. To assess
the apoptotic rate in addition to MGG, we applied two other
morphological methods, namely ISEL for DNA fragmentation and
immunocytochemistry for the active form of caspase 3. A
concentration of 50mM CDDP was defined as the optimal drug
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Figure 1 Dose- and time-dependent effects of CDDP on NCCIT cells. (A) Tumour cells were treated with different CDDP concentrations. After 24h,
the apoptotic rate of tumour cells was assessed by MGG staining, immunocytochemistry for the active form of caspase-3 and ISEL for DNA fragmentation.
Representative photomicrographs of active caspase-3 (black cytoplasmatic signals) and of DNA fragmentation (black nuclear signals) in untreated (control)
and drug-treated NCCIT cells illustrate increased apoptosis of tumour cells treated with 50mM CDDP when compared to the control. The diagram shows
quantification of tumour cell apoptosis with MGG staining following application of different CDDP concentrations. (B) Tumour cells were treated with
50mM CDDP. After 6, 9, 12 and 24h, the apoptotic rate of tumour cells was assessed. Representative photomicrographs of active caspase-3 and of DNA
fragmentation in untreated and CDDP-treated NCCIT cells illustrate increased apoptosis of tumour cells 24h after drug treatment. The diagram shows
quantification of tumour cell apoptosis with MGG staining in time dependency. Data presented in (A) and (B) are the mean of triplicates; similar results were
obtained in three separate experiments.
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sconcentration to elicit apoptosis in 9375% of tumour cells within
24h (Figure 1). Experiments with this optimal CDDP concentra-
tion revealed that the apoptotic rate of NCCIT cells increased from
972% at the beginning to 1571% at 6h, 3172% at 9h, 5474% at
12h and 9375% at 24h after drug application (Figure 1).
Analysis of apoptosis-regulating genes following CDDP
treatment
On the strength of the evidence that the apoptotic rate of tumour
cells showed an initial increase at 6h after drug treatment, we
performed a cDNA macroarray analysis to compare the expression
pattern of 205 apoptosis-related genes in NCCIT cells before and
6h after application of 50mM CDDP. Most of the genes analysed,
however, were either not detectable (no signal) or only weakly
expressed in NCCIT cells (weak signals) and did not reveal any
down- or upregulation after drug treatment. p53, the p53-regulated
gene mdm-2 and genes from the Bcl-2 family belonged to this
group, as reported by others (Burger et al, 1997; Kersemaekers
et al, 2002) (Table 1). The expression level of five genes including
IGFBP-2, AP-1, CDC25A, GADD45 and ID-1 was decreased in
treated cells compared to the levels in untreated cells (Table 1).I n
contrast, the expression of 12 genes including those involved in
cell cycle and apoptosis (e.g. CDK4, CDK5, cyclin B1 and caspase-
3), or in signal transductions (e.g. GRB2 and PLK1) was increased
in CDDP-treated cells when compared to untreated ones (Table 1).
The fourth category of genes included those with a sustained high
level of expression before and after drug treatment. MEK1/2,
RHOA, Prefoldin and N-myc belonged to this category of genes
(Table 1).
Owing to the high and sustained expression level of MEK1/2
mRNA, and the fact that activation of the MEK–ERK pathway
cannot only hamper but also promote the sensitivity of tumour
cells to CDDP (Persons et al, 1999; Wang et al, 2000), in the follow-
up this study was focused on the role of MEK in the course of
drug-induced apoptosis. At first, we proved the expression of
MEK1/2 mRNA by a second method. Semiquantitative RT–PCR
confirmed the results from the macroarray and revealed that in
NCCIT cells the transcription level of both MEK1 and MEK2
mRNAs remained constant after drug treatment (Table 1, Figure 2).
As control, we investigated the expression level of MEK1/2 mRNA
after heat- and mechanically induced necrosis of the NCCIT cell
line. Results showed that stress stimuli leading to cell death
without primary DNA damage (heat- or mechanically induced
necrosis) do not elicit any significant change in the expression
level of MEK1/2 mRNA. Figure 2 illustrates the expression level of
MEK1 and MEK2 mRNAs following heat-induced necrosis in
NCCIT cells.
CDDP-induced activation of the MEK–ERK signalling
pathway
Next, lysates from untreated and drug-treated tumour cells were
analysed by Western blot for the expression of MEK1/2 and its
substrate ERK1/2. The same blots were stripped and analysed with
antibodies recognising dually phosphorylated MEK (pMEK) 1/2 or
dually phosphorylated ERK (pERK) 1/2 to verify the active fraction
of each protein in our experiments. Results illustrated that, despite
high expression, MEK1/2 and ERK1/2 proteins were mainly
unphosphorylated in untreated NCCIT cells (Figure 3). However,
phosphorylation of MEK1/2 and ERK1/2 proteins began to
increase at 6h and was at its highest at 12h after CDDP treatment,
a course which has been observed in growth factor- or oxidant-
mediated MEK–ERK activation in many cell types (Jimenez et al,
1997; Wang et al, 1998). Interestingly, MEK1 and ERK2 seem to be
more strongly phosphorylated than MEK2 and ERK1.
Blocking of CDDP-induced apoptosis by MEK inhibitors
To study whether ERK activation is required for CDDP-induced
apoptosis in NCCIT cells, two chemical MEK1/2 inhibitors, U0126
and PD98059, were used. Cells were treated with various doses of
MEK1/2 inhibitors simultaneously to the addition of 50mM CDDP.
Both inhibitors reduced the grade of ERK phosphorylation
(Figure 4). Morphological quantification of apoptotic cells by
MGG, immunostaining for active caspase 3 and ISEL for
fragmented DNA demonstrated that application of an inhibitor
significantly reduced the CDDP-induced apoptosis of tumour cells
in a dose-dependent manner when compared to controls. For
example, application of 30mM U0126 was capable of decreasing the
rate of apoptosis of drug-treated cells from approximately 95 to
about 50%. Results are shown in Figure 4. To rule out that MEK
inhibitors unspecifically influence the cell cycle and thereby
interfere with apoptosis, flow cytometric DNA analysis of NCCIT
cells were carried out 6 and 24h after treatment with U0126 or
PD98059 (50mM). Results showed that MEK inhibitors do not
impair the cell cycle of NCCIT cells (Figure 4).
MEK–ERK activation results in caspase activity
By applying caspase assays, we first analysed the activation of
initiating caspase-8 and -9 and of the executing caspase-3 in the
course of CDDP-induced apoptosis in NCCIT cells. Results
demonstrated that the caspase-8 and -9 activity increased 3–4-
fold, and the activity of caspase-3 about 14–16-fold at 24h after
CDDP application (Figure 5). Next we investigated the activity of
caspase-8, -9 and -3 following MEK inhibition to ascertain that the
increased activation of these caspases depended on the MEK–ERK
activation. Indeed, application of MEK inhibitors (U0126 or
PD98059) substantially decreased the activity of all three caspases
(Figure 5). We studied then the biological influence of each caspase
for apoptosis on drug-treated NCCIT cells. We noted that 24h after
CDDP application, the apoptotic rate of tumour cells decreased
from 9375t o7 5 74% following inhibition of caspase-8, to
8573% following inhibition of caspase-9, or to 4976% following
inhibition of caspase-3 (Figure 5). Moreover, we observed that the
activity of caspase-3 was only weakly reduced when caspase-8 or -9
Table 1 Expression of apoptosis-related genes in NCCIT cells following
CDDP treatment
CDK4 Cyclin-dependent kinase 2 Increased
CDK5 Cyclin-dependent kinase 4 Increased
Cyclin B1 Cyclin B Increased
Caspase-3 Caspase-3 Increased
GRB-2 Growth factor receptor-bound protein 2 Increased
PLK Polo-like kinase Increased
p53 p53 tumor suppressor protein Unchanged
mdm-2 p53-binding mouse double minute 2 homolog Unchanged
bcl-2 B-cell leukemia/lymphoma protein 2 Unchanged
bax Bcl-2-associated X protein membrane Unchanged
IGFBP-2 IGF-binding protein 2 Decreased
AP-1 Transcription factor Decreased
CDC25A Cell division cycle 25 homolog A Decreased
GADD45 Growth arrest and DNA damage-inducible
protein 45
Decreased
ID-1 Inhibitor of DNA-binding protein 1 Decreased
MEK1/2 Mitogen-activated protein kinase kinase 1/2 Sustained high
RHOA Ras homolog gene family member Sustained high
Prefoldin 5 c-myc-binding protein Sustained high
N-myc N-myc Sustained high
Two RNA preparations were isolated from untreated and CDDP-treated NCCIT
cells. RNAs were reverse transcribed, and generated cDNA probes were hybridised
to cDNA macroarray membrane filters. Gene transcripts that displayed two-fold or
greater changes were considered significant. Only 17 differentially expressed genes
were identified among 205 genes investigated.
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swas inhibited (Figure 5). Thus, caspase-8 and -9 seem to play only
a supporting role, whereas caspase-3 is the main caspase
responsible for the CDDP-induced apoptosis in NCCIT cells.
Selectivity of CDDP-induced apoptosis
To prove whether activation of the MEK/ERK pathway seen in the
p53-mutated TGCT cell line NCCIT is also required for the CDDP-
induced apoptosis in human neoplastic germ cells with wt-p53,
NTERA cells were treated with CDDP. As reported by others
(Chresta et al, 1996; Burger et al, 1999), CDDP treatment led to
apoptosis of NTERA cells dose and time dependently (data not
shown). Western analysis showed that following CDDP application
(50mM) both MEK and ERK were phosphorylated and simulta-
neous treatment of NTERA cells with CDDP and one of the MEK1/
2 inhibitors U0126 (30mM) or PD98059 (50mM) significantly
reduced the apoptosis. Notably, the effect of MEK1/2 inhibitors
on the apoptotic rate of drug-treated NTERA cells was as efficient
as that seen in NCCIT cells (Figure 6). Thus, we concluded that the
CDDP-induced apoptosis of NCCIT and NTERA cells was, at least
partially, p53 independent and mediated by the MEK/ERK
signalling pathway.
Specificity of CDDP-induced apoptosis
To examine the role of the MEK–ERK signalling pathway in the
induction of apoptosis and/or necrosis following other stress
stimuli, NCCIT cells were treated with various doses of vinblastin
(15–30mM) – as a relevant drug in the therapy of TGCT – and of
hydrogen peroxide (H2O2; 300–1200mM) or underwent heat (451C
up to 60min) or mechanical stress (multiple pipetting). Figure 7
demonstrates that treatment with vinblastin and H2O2 led to
apoptosis of NCCIT cells in a dose-dependent manner and was
conducted by ERK activation. As expected, MEK inhibition led to a
significant reduction in apoptosis in NCCIT cells and was as
effective as that seen in experiments with CDDP and MEK1/2
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Figure 2 MEK1/2 mRNA expression in untreated and CDDP-treated NCCIT cells. (A) Two RNA preparations from untreated and CDDP-treated
NCCIT cells were reverse transcribed and hybridised to cDNA macroarray membrane filters. Sections from two representative autoradiographies show
sustained expression of MEK1/2 in untreated (control) and CDDP-treated (50mM) NCCIT cells 6h after drug treatment (arrows). (B) semiquantitative real-
time RT–PCR of MEK1 and MEK2 mRNA confirms that the expression level of both transcripts remains constant in CDDP-treated NCCIT cells (open
arrows, left) compared to untreated ones (closed arrows, right). (C) as control, the expression level of MEK1 and MEK2 mRNA after heat-induced necrosis
of the NCCIT cell line was analysed. Results demonstrate that in the course of heat-induced necrosis, the expression level of MEK mRNAs is not changed
(-K-) compared to untreated ones (-’-).
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sinhibitors U0126 or PD98059 (data not shown). Results also show
that stress stimuli leading to cell death without primary DNA
damage (heat- or mechanically induced necrosis) elicit ERK
phosphorylation (Figure 7).
DISCUSSION
The present study was focused on p53-independent mechanisms
involved in CDDP-induced apoptosis of the human neoplastic
germ cell line NCCIT, the p53 protein of which is known to remain
inactive during the course of drug-induced apoptosis (Burger et al,
1997; Burger et al, 1999). To address this issue, we first studied
dose- and time-dependent effects of CDDP on NCCIT cells.
Experiments indicated that following application of an optimal
concentration of 50mM CDDP, the apoptotic rate of tumour cells
increased from approximately 10% at the beginning to about 95%
at 24h. Significant differences in the degree of apoptosis between
CDDP-treated and untreated cells were, however, not observed
before 6h. In the light of previous data indicating that CDDP
exerts its cytotoxicity via the formation of mono-, inter-, and
intrastrand CDDP-DNA adducts, which can ultimately result in cell
cycle arrest at G1, S or G2-M and in the induction of apoptosis
(Fichtinger-Schepman et al, 1985; Sorenson and Eastman, 1988;
Eastman, 1990), we hypothesised that within 6h after application
CDDP upregulated proapoptotic and/or downregulated antiapop-
totic genes, thus mediating apoptosis in NCCIT cells. For a
scanning view of differentially regulated genes, we investigated the
expression profile of 205 apoptosis-related genes by applying a
commercially available cDNA macroarray. As expected, no
significant changes were found in the expression levels of p53
and the p53-dependent gene mdm-2 upon drug application. In
addition to a few differentially regulated genes with unknown
function for the course of CDDP-induced apoptosis, we noted a
sustained high level of MEK1/2 mRNA expression in NCCIT cells
before and after drug treatment.
MEK1 and MEK2 are protein kinases that when activated
(phosphorylated) are believed to dually phosphorylate only ERK1
and ERK2, thereby increasing the enzymatic activity of ERKs
approximately 1000-fold over the activity found with the basal or
monophosphorylated forms (Traverse et al, 1992; Lenormand et al,
1993, Robbins et al, 1993). The consequence is a phosphorylation
of diverse protein kinases, transcription factors, and even
cytoskeletal proteins leading to paradoxical cellular responses
ranging from proliferation to apoptosis (Peyssonnaux and
Eychene, 2001; Djeu et al, 2002; Lee and McCubrey, 2002).
Interestingly, similar conflicting reports also exist on the role of
the MEKs and ERKs in CDDP-induced apoptosis. For example, the
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Figure 3 CDDP-induced activation of the MEK/ERK pathway in NCCIT
cells. NCCIT cells were treated with 50mM CDDP for 2h, after which cell
lysates were investigated for the expression and activation (phosphoryla-
tion) of MEK1/2 and ERK1/2 by Western blot analysis in the time course.
Upper panel illustrates the expression of MEK1/2 and its activation
(phosphorylation) following CDDP treatment. Lower panel demonstrates
results from Western blots of ERK1/2 and its activated (phosphorylated)
form pERK1/2 in the time course after CDDP treatment. Note that MEK1
and ERK2 are more strongly phosphorylated than MEK2 and ERK1.
Expression of actin was used to control equal protein loading.
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Figure 4 Blocking of CDDP-induced apoptosis by MEK inhibitors. To
investigate whether phosphorylation of ERK1/2 is required for the CDDP-
induced apoptosis of NCCIT cells, two different MEK inhibitors, U0126 and
PD98059, were applied in addition to 50mM CDDP. (A) Western blot
analysis with an anti-phospho-ERK1/2 antibody shows the inhibition of
ERK1/2 activation by MEK1/2 inhibitors (U0126, 10 and 30mM; PD98059,
30 and 50mM). (B) The diagram shows quantification of tumour cell
apoptosis with MGG staining dependent on ERK blockage by different
concentration of MEK inhibitors after 24h. Data are the mean of triplicates;
similar results were obtained in three separate experiments. (C) Flow
cytometric DNA analysis of NCCIT cells treated with the MEK inhibitor
U0126 (50mM) demonstrates that following drug treatment, the cell cycle
of NCCIT cells is not changed.
ERK 1/2 mediates cisplatin-induced apoptosis in TGCT cell lines
S Schweyer et al
594
British Journal of Cancer (2004) 91(3), 589–598 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sactivity of the MEK–ERK signalling pathway seems to reduce
sensitivity to CDDP in ovarian carcinoma cells, whereas phos-
phorylation of MEK and ERK has been found to be essential for the
CDDP-induced apoptosis in cervical carcinoma cells (Persons et al,
1999; Wang et al, 2000).
To prove the results from the cDNA macroarray analysis and to
address the role of the MEK–ERK signalling pathway in neoplastic
germ cells, semiquantitative RT–PCR and immunoblots were
carried out. The findings from the real-time RT–PCR were in
agreement with those from the cDNA macroarray analysis and
indicated that up to 24h after CDDP application the expression
level of MEK1 and MEK2 mRNAs remained constant. Immuno-
blots supported these data and demonstrated that both MEK1/2
and ERK1/2 proteins were strongly expressed but were mainly
unphosphorylated and thereby inactive in untreated tumour cells.
Interestingly, CDDP treatment resulted in high and sustained
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Figure 5 MEK–ERK activation results in caspase activity. (A) NCCIT cells were treated with CDDP (50mM) in the presence or absence of the MEK
inhibitor U0126 (30mM) as described in Materials and methods. After cell lysis, the activity of caspase-3, -8 and -9 was determined using specific fluorogenic
substrates: Ac-DEVD-MCA (for caspase-3), Ac-IETD-MCA (for caspase-8) and Ac-LEHD-MCA (for caspase-9). The data are expressed as the increase in
fluorescence as a function of time. Note that the Y-axis ranges from 0 to 20 for caspase-3, from 0 to 2 for caspase-8 and from 0 to 1.5 for caspase-9. (B)
NCCIT cells were treated with CDDP (50mM) in the presence or absence of Ac-DEVD-CHO as caspase-3 inhibitor, or Ac-IETD-CHO as caspase-8
inhibitor or Z-LEHD-FMK as caspase-9 inhibitor. Diagrams show quantification of tumour cell apoptosis with MGG staining in time dependency. (C) NCCIT
cells were treated with CDDP (50mM) in the presence or absence of Ac-IETD-CHO as caspase-8 inhibitor or Z-LEHD-FMK as caspase-9 inhibitor. After cell
lysis, the activity of caspase-3 was determined. Results show the increase in fluorescence as a function of time. Data presented in (A–C) are the mean of
triplicates; similar results were obtained in three separate experiments.
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sactivation of MEK, particularly MEK1, and ERK, especially ERK2,
which was strongly correlated to the apoptosis of tumour cells.
Thus, it is tempting to speculate that a prolonged period of
excessive phosphorylation of ERK may be necessary for its
biological effect on TGCT as demonstrated for other cells types
(Traverse et al, 1992; Lenormand et al, 1993).
To clarify the importance of the MEK–ERK pathway for the
apoptosis of drug-treated NCCIT cells, we interrupted the pathway
activity by using two different MEK inhibitors. Experiments
revealed that the MEK inhibitors not only downregulated the level
of ERK phosphorylation but also reduced the apoptotic rate of
CDDP-treated NCCIT cells, as previously reported for the cervical
carcinoma cell line HeLa (Wang et al, 2000). Results from RT–
PCR and Western analyses, however, suggested that the CDDP-
induced apoptosis in NCCIT cells depended on phosphorylation of
MEK and ERK constitutively expressed in tumour cells and did not
require any MEK/ERK de novo expression.
Considering the pivotal role of caspases in the initiation and
execution of apoptosis (Thornberry and Lazebnik, 1998), we next
analysed the activation of caspase-3, -8 and -9 following CDDP
treatment of NCCIT cells. Caspases are divided into two
subfamilies, initiator (e.g. caspase-8) and executor (e.g. caspase-
3), based on their roles in the apoptotic signalling cascade
(Salvesen and Dixit, 1997; Nunez et al, 1998). Depending on
apoptotic signal and cell type, activation of initiator caspases may
lead to mitochondria-dependent and/or -independent activation of
executor caspases; whereas the former requires cytochrome c
release and activation of caspase-9 as consequences of mitochon-
dria damage, the latter is characterised by a cytochrome-c- and
caspase-9-independent activation of executor caspases (Krammer,
2000). In this study, elevated caspase activity after CDDP
application was found in caspase-3, -8 and -9. However, caspase-
3 activation seemed to be more important for the course of
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Figure 6 Selectivity of CDDP-induced apoptosis. NTERA cells were
treated with 50mM CDDP in the presence or absence of the MEK inhibitors
U0126 (30mM) or PD98059 (50mM), as described in Material and methods.
(A) After 24h, tumour cells were lysed and investigated for the expression
and activation (phosphorylation) of ERK1/2 by Western blot analysis. (B)
the diagram shows quantification of tumour cell apoptosis with MGG
staining dependent on ERK blockage by MEK inhibitors after 24h. Data are
the mean of triplicates; similar results were obtained in three separate
experiments.
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Figure 7 Specificity of CDDP-induced apoptosis. (A) NCCIT cells were treated with CDDP (50mM), vinblastin (30mM)o rH 2O2 (1200mM). After 24h,
the apoptotic rate of tumour cells was assessed by immunocytochemistry for the active form of caspase-3 and MGG staining. Representative
photomicrographs of caspase-3 (black cytoplasmatic signals) in NCCIT cells illustrate increased caspase activity in tumour cells following treatment. The
diagram shows quantification of tumour cell apoptosis with MGG staining. Data are the mean of triplicates; similar results were obtained in three separate
experiments. A fraction of tumour cells was lysed and investigated for the expression and activation (phosphorylation) of ERK1/2 by Western blot analysis.
(B) To examine the role of the MEK–ERK signalling pathway in the course of necrosis, NCCIT cells underwent heat (451C up to 60min) or mechanical
stress (multiple pipetting). Results demonstrate that stress stimuli leading to cell death without primary DNA damage (heat- or mechanically induced
necrosis) also elicit ERK phosphorylation.
ERK 1/2 mediates cisplatin-induced apoptosis in TGCT cell lines
S Schweyer et al
596
British Journal of Cancer (2004) 91(3), 589–598 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sapoptosis than caspase-8 and -9 activation, because blockade of
caspase-3 inhibited apoptosis to a greater extent than the blockade
of caspase-8 or -9. Consistently, the activity of caspase-3 was only
moderately abolished when caspase-8 or -9 was blocked. Taking
the published data on the involvement of caspase-8 and -9 in
mitochondria-dependent apoptosis into account (Krammer, 2000),
we consider the possibility that ERK-mediated apoptosis in NCCIT
cells is mainly induced by a mitochondria-independent activation
of caspase-3.
We investigated then whether the ERK-mediated apoptosis is
specific for NCCIT, and whether other apoptosis-inducing agents
also activate ERK in NCCIT cells. Experiments on the human
malignant germ cell line NTERA possessing the wild-type p53 had
indicated that NTERA cells were as sensitive to CDDP as NCCIT
cells, and apoptosis of NTERA cells was also mediated by ERK.
Consequently, when MEK was blocked by specific inhibitors, the
apoptotic rate of treated NTERA cells was reduced significantly.
Thus, activation of the MEK–ERK pathway leads to apoptosis
independent from the p53 status. Importantly, experiments with
another relevant chemotherapeutic drug (vinblastin) and reactive
oxygen species (H2O2) revealed that following treatment of
neoplastic germ cells ERK was phosphorylated, and tumour cells
underwent apoptosis. Thus, activation of the MEK–ERK pathway
enhances apoptosis not only in NCCIT but also in NTERA cells and
the ERK-mediated apoptosis in NCCIT cells is not limited to
CDDP. To answer the question whether ERK activation can also be
induced by nonapoptotic stimuli inducing cell death without
primary DNA damage, NCCIT cells underwent heat or mechanical
stress. Results showed that these stress stimuli also led to the ERK
phosphorylation. In conclusion, phosphorylation of ERK is not
specific for CDDP, because other apoptosis (e.g. Vinblastin)- and
necrosis-inducing stimuli (e.g. heat) are also capable to activate the
ERK signalling pathway.
The question is, however, how does the MEK–ERK pathway
becomes active following treatment with drugs (e.g. CDDP or
vinblastin) or reactive oxygen species (e.g. H2O2). In this respect,
recent data support the hypothesis that toxic substances such as
reactive oxygen species may inhibit phosphatases (e.g. protein
phosphatase or protein tyrosine phosphatases) and thereby
contribute to the activation of ERK (Lee and Esselman, 2002)
Another scenario may be that CDDP ligates growth
factor receptors, thereby activating the MEK–ERK pathway, as
suggested for the cervical carcinoma cell line HeLa (Wang et al,
2000). Indeed there are even some reports demonstrating that
TGCT express an aberrant platelet-derived growth factor a-
receptor, which is hypothetically capable of activating the MEK–
ERK pathway upon ligation (Kollmannsberger et al, 2002; Palumbo
et al, 2002).
Other remaining questions are whether other kinases (e.g. JNK
or p38) collaborate with MEK–ERK in apoptosis of malignant
germ cells, as shown for some tumours (Boldt et al, 2002), and –
more importantly – which downstream effectors are involved in
MEK–ERK-mediated apoptosis?
In conclusion, the data suggest that CDDP mediates its p53-
independent apoptosis-inducing effect on the malignant human
testicular germ cells through activation of the MEK–ERK
signalling pathway that culminates in activation of the executor
caspase-3 and thereby in programmed cell death. The data would
also suggest that an antitumour therapy with CDDP should not be
combined with MEK inhibitors because such combination might
be antagonistic and not of benefit for the outcome of patients with
TGCT.
REFERENCES
Bach BA, Knape WA, Edinger MG, Tubbs RR (1991) Improved sensitivity
and resolution in the flow cytometric DNA analysis of human solid
tumor specimens. Use of in vitro fine-needle aspiration and uniform
staining reagents. Am J Clin Pathol 96: 615–627
Boldt S, Widle UH, Kolch W (2002) The role of MAPK pathways in the
action of chemotherapeutic drugs. Carcinogenesis 23: 1831–1838
Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G (1997) Lack of
correlation between cisplatin-induced apoptosis, p53 status and expres-
sion of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J
Cancer 73: 592–599
Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH,
Jochemsen AG, Stoter G (1999) Distinct p53-independent apoptotic cell
death signalling pathways in testicular germ cell tumour cell lines. Int J
Cancer 81: 620–628
Chresta CM, Masters JRW, Hickman JA (1996) Hypersensitivity
of human testicular tumors to etoposide-induced apoptosis is
associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res
56: 1834–1841
Djeu JY, Jiang K, Wei S (2002) A view to a kill: signals triggering
cytotoxicity. Clin Cancer Res 8: 636–640
Eastman A (1990) Activation of programmed cell death by anticancer
agents: cisplatin as a model system. Cancer Cells 2: 275–280
Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci
USA 99: 4592–4595
Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH,
Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloro-
platinum(II) with DNA: formation, identification, and quantitation.
Biochemistry 24: 707–713
Higby DJ, Wallace Jr HJ, Albert DJ, Holland JF (1974) Diaminodichloro-
platinum: a phase I study showing responses in testicular and other
tumors. Cancer 33: 1219–1225
Jimenez LA, Zanella C, Fung H, Janssen YM, Vacek P, Charland C,
Goldberg J, Mossman BT (1997) Role of extracellular signal-regulated
protein kinases in apoptosis by asbestos and H2O2. Am J Physiol 273:
L1029–L1035
Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW,
Bokemeyer C, Looijenga LHJ (2002) Role of P53 and MDM2 in
treatment response of human germ cell tumors. J Clin Oncol 20:
1551–1561
Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW,
Looijenga LH, Bokemeyer C (2002) Absence of c-KIT and members of
the epidermal growth factor receptor family in refractory germ cell
cancer. Cancer 95: 301–308
Krammer PH (2000) CD95’s deadly mission in the immune system. Nature
407: 789–795
Lee Jr JT, McCubrey JA (2002) The Raf/MEK/ERK signal transduction
cascade as a target for chemotherapeutic intervention in leukemia.
Leukemia 16: 486–507
Lee K, Esselman WJ (2002) Inhibition of PTPs by H(2)O(2) regulates
the activation of distinct MAPK pathways. Free Radic Biol Med 33:
1121–1132
Lenormand P, Sardet C, Pages G, L’Allemain G, Brunet A, Pouyssegur, J
(1993) Growth factors induce nuclear translocation of MAP kinases
(p42mapk and p44mapk) but not of their activator MAP kinase kinase
(p45mapkk) in fibroblasts. J Cell Biol 122: 1079–1088
Lutzker SG, Levine AJ (1996) A functionally inactive p53 protein in
teratocarcinoma cells is activated by either DNA damage or cellular
differentiation. Nat Med 2: 804–810
Nunez G, Benedict MA, Hu Y, Inohara N (1998) Caspases: the proteases of
the apoptotic pathway. Oncogene 17: 3237–3245
Palumbo C, van Roozendaal K, Gillis AJ, van Gurp RH, de Munnik H,
Oosterhuis JW, van Zoelen EJ, Looijenga LH (2002) Expression of the
PDGF alpha-receptor 1.5kb transcript, OCT-4, and c-KIT in human
normal and malignant tissues. Implications for the early diagnosis of
testicular germ cell tumours and for our understanding of regulatory
mechanisms. J Pathol 196: 467–477
Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Cisplatin-induced
activation of mitogen-activated protein kinases in ovarian carcinoma
cells: inhibition of extracellular signal-regulated kinase activity increases
sensitivity to cisplatin. Clin Cancer Res 5: 1007–1014
ERK 1/2 mediates cisplatin-induced apoptosis in TGCT cell lines
S Schweyer et al
597
British Journal of Cancer (2004) 91(3), 589–598 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sPeyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new
concepts of activation. Biol Cell 93: 53–62
Raabe T, Rapp UR (2002) KSR – a regulator and scaffold protein of the
MAPK pathway. Sci STKE 136: PE28
Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, Cobb
MH (1993) Regulation and properties of extracellular signal-regulated
protein kinases 1 and 2 in vitro. J Biol Chem 268: 5097–5106
Salvesen GS, Dixit VM (1997) Caspases: intracellular signaling by
proteolysis. Cell 91: 443–446
Sorenson C, Eastman A (1988) Mechanism of cis-diamminedichloroplati-
num(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand
breaks. Cancer Res 48: 6703–6707
Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:
1312–1316
Traverse S, Gomez N, Paterson H, Marshall C, Cohen P (1992) Sustained
activation of the mitogen-activated protein (MAP) kinase cascade may
be required for differentiation of PC12 cells. Comparison of the effects
of nerve growth factor and epidermal growth factor. Biochem J 288:
351–355
Wang X, Martindale JL, Holbrook NJ (2000) Requirement for
ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:
39435–39443
Wang X, Martindale JL, Liu Y, Holbrook NJ (1998) The cellular
response to oxidative stress: influences of mitogen-activated
protein kinase signalling pathways on cell survival. Biochem J 333:
291–300
Wyllie A, Kerr H, Currie AR (1980) Cell death: the significance of apoptosis.
Int Rev Cytol 68: 251–306
ERK 1/2 mediates cisplatin-induced apoptosis in TGCT cell lines
S Schweyer et al
598
British Journal of Cancer (2004) 91(3), 589–598 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s